EGFR and neoplasm: Therefore, this study was designed to take advantage of the ORR of EGFR-TKI treatment (>70%), disease control rate (>90%), and PFS (9-11 months) (29–31) based on the dosimetric property that a ≥15% shrinkage rate in the primary tumour volume can significantly reduce the low-dose volume to the whole lung and reduce radiation injury (27).